OTC · ENZB
Enzo Biochem, Inc.
$0.70-$0.00 (-0.16%)
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
Loading market information…
NASDAQ · CEMI · USD
Stock price, earnings
Quote as of Apr 27, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Chembio Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Chembio Diagnostics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Chembio Diagnostics, Inc., along with its subsidiaries, specializes in creating, producing, and bringing to market point-of-care (POC) diagnostic tests used for identifying and diagnosing various diseases. Their current product offerings include tests for critical conditions like COVID-19, HIV/Syphilis, and the Zika virus. Beyond these, the company is dedicated to advancing diagnostics for a wide array of other infectious diseases, such as malaria, dengue, chikungunya, Chagas disease, Ebola, leishmaniasis, Lassa fever, Marburg virus, leptospirosis, rickettsia, and Burkholderia infections. These diagnostic tools are sold under well-known brand names including STAT-PAK, SURE CHECK, STAT VIEW, and DPP. Chembio distributes its products directly and through various partners to a diverse global customer base. This clientele includes medical laboratories, hospitals, government and public health agencies, non-governmental organizations (NGOs), medical professionals, and retail outlets across the United States and worldwide. The company engages in strategic partnerships with prominent organizations such as the Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics. Additionally, Chembio collaborates with several key U.S. government entities, including the Centers for Disease Control and Prevention (CDC), the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture (USDA). Founded in 1985, Chembio Diagnostics, Inc. has its headquarters located in Hauppauge, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $4.18M-35.28% vs estimate |
| Q1 2021 | May 6, 2021 | -$0.22+26.67% vs estimate | $5.37M-23.81% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.70-$0.00 (-0.16%)
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
$0.45$0.00 (0.0%)
Lucira Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$2.27+$0.01 (+0.44%)
Conformis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$0.14$0.00 (0.0%)
Titan Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.33% below the high.
$2.67+$2.67 (+100.0%)
Psychemedics Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.61+$0.61 (+100.0%)
23andMe Holding Co.’s quoted price sits in the lower half of its reported 52-week range, 95.25% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
